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Conclusion of the opinion 
The calculation for margin of safety in this Opinion is based on a 39-week dermal toxicity 
study in the mini-pig, as no repeated dose toxicity study with the nano-sized material is 
available in rats. Also, dermal penetration data are not available for mini-pig skin. The 
SCCS has based this Opinion on the overall weight of evidence that suggests a very low 
absorption of MBBT in human skin, and the lack of adverse effects in mini-pigs up to the 
highest dose tested (1000mg a.i./kg bw/day) over 39 weeks. These together indicate 
that dermal application of nano-sized MBBT with regard to systemic effects is not a safety 
concern. The SCCS has therefore concluded that the use of MBBT [2,2’-methylene-bis-
(6(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)] in nano-structured form 
with the following characteristics as a UV-filter at a concentration up to 10% in dermally 
applied cosmetic products is considered to not pose a risk of adverse effects in humans 
after application on healthy, intact skin: 
The material has a purity of ≥98.5% with the isomer faction not exceeding 1.5%, and 
the impurity profile not significantly different from that indicated in section 3.1.5. 
The material has a median particle size (d0.5) of 120 nm or larger in terms of mass 
distribution, and/or 60 nm or larger in terms of number size distribution (by laser 
diffraction).  
The material complies with other physicochemical specifications of the evaluated material 
as listed under section 3.1 of this opinion in terms of chemical identity, physical form, 
chemical composition, solubility, zeta potential, etc. 
In view of the limited available information on inhalation toxicity, which indicates severe 
inflammatory effects of microfine MBBT in the respiratory tract, caution is warranted 
against the use of the material in applications that could lead to exposure of the 
consumer’s lungs by inhalation. This Opinion therefore does not apply to such 
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applications that might lead to exposure of the consumer’s lungs to MBBT nanoparticles 
by inhalation. 
It should also be noted that this Opinion is based on the currently available scientific 
evidence, which shows an overall very low dermal absorption of MBBT in nano- or larger 
particle forms. If any new evidence emerges in the future to show that the nano-form of 
MBBT used in cosmetic products can penetrate skin (healthy, compromised, sunburnt or 
damaged skin) in any significant amounts to reach viable cells, the SCCS may consider 
revising this assessment.  
The in vitro genotoxicity assessment of MBBT was negative in two different test systems. 
These tests were appropriately applied and demonstrate that there was no evidence for 
chromosomal damage or mutagenicity when mammalian cells were exposed to both non-
micronised and nano-forms of MBBT. Although these test data are accepted by the SCCS, 
no experimental data on uptake/internalisation of the particle by cells has been provided.  
In addition, the SCCS has the following concerns: 
- In the study in rats, clinical effects (pain and vocalisation) after dermal application were 
noted at concentrations of 20% (500mg a.i. /kg bw/d and higher). In the carcinogenicity 
study, scabs were seen at a dose level of 100 mg a.i./kg/bw/day and higher. It is 
worthwhile to monitor possible irritation effects via the cosmetovigilance programs.  
- Given the physicochemical properties (high lipophilicity) of the substance, potential 
bioaccumulation in selected tissues is of concern, especially over long-term use.  
This opinion does not address the effects of MBBT on the environment. 
Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on 2,2’-
methylene-bis-(6(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) nano, 
SCCS/1546/15, 25 March 2015, revision of 25 June 2015 
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Opinion of the Scientific Committee on Consumer safety (SCCS) - Opinion on the use of 2,2'-5 
methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) (nano) – S79 -  in 6 
cosmetic products  7 
 8 
 9 
The substance 2,2'-methylene-bis-(6(2H-benotriazol-2-yl)-4-(l, 1,3,3- 10 
tetramethylbutyl)phenol) (MBBT) (CAS No 103597-45-1), Methylene bis-benzotriazolyl 11 
tetramethylbutylphenol (INCI) (COLIPA S79) is currently regulated in Entry 23 Annex VI 12 
of the Cosmetics Regulation (EC) 1223/2009 with the maximum concentration of 10% in 13 
cosmetic products such as sunscreens, day care products and skin lightening products. 14 
The safety of mentioned use conditions was confirmed by the Scientific Committee on 15 
Cosmetic Products and Non-Food (SCCNFP) in 1998 following submission I by COLIPA1 16 
(SCCNFP/0080/98)2. 17 
Submission II on MBBT was submitted to the Scientific Committee on Consumer Safety 18 
(SCCS) in January 2013 to assess the safety of its nano form. The SCCS opinion 19 
concluded that: 20 
"Since no appropriate data on genotoxicity of nano form of MBBT were provided, no 21 
conclusion on the safety of this substance can be drawn. However regarding systemic 22 
                                                          
1 COLIPA - now Cosmetics Europe,- European Cosmetics Toiletry and Perfumery Association 
2
 http://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/sccnfp_opinions_97_04/sccp_out73_en.htm 
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effects there seems no concern for the dermal application of nano-sized MBBT" 1 
(SCCS/1460/11)3. 2 
In August 2014 the applicant has transmitted a new safety dossier that summarizes 3 
analytical and toxicological results obtained for genotoxicity studies performed with nano 4 
and non-nano forms of MBBT. 5 
The calculation for margin of safety in this Opinion is based on a 39-week dermal toxicity 6 
study in the mini-pig, as no repeated dose toxicity study with the nano-sized material is 7 
available in rats. Also, dermal penetration data are not available for mini-pig skin. The 8 
SCCS has based this Opinion on the overall weight of evidence that suggests a very low 9 
absorption of MBBT in human skin, and the lack of adverse effects in mini-pigs up to the 10 
highest dose tested (1000mg a.i./kg bw/day) over 39 weeks. These together indicate 11 
that dermal application of nano-sized MBBT with regard to systemic effects is not a safety 12 
concern. The SCCS has therefore concluded that the use of MBBT [2,2’-methylene-bis-13 
(6(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)] in nano-structured form 14 
with the following characteristics as a UV-filter at a concentration up to 10% in dermally 15 
applied cosmetic products is considered to not pose a risk of adverse effects in humans 16 
after application on healthy, intact skin: 17 
The material has a purity of ≥98.5% with the isomer faction not exceeding 1.5%, and 18 
the impurity profile not significantly different from that indicated in section 3.1.5. 19 
The material has a median particle size (d0.5) of 120 nm or larger in terms of mass 20 
distribution, and/or 60 nm or larger in terms of number size distribution (by laser 21 
diffraction).  22 
The material complies with other physicochemical specifications of the evaluated material 23 
as listed under section 3.1 of this opinion in terms of chemical identity, physical form, 24 
chemical composition, solubility, zeta potential, etc. 25 
                                                          
3 http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccso 129.pdf  
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In view of the limited available information on inhalation toxicity, which indicates severe 1 
inflammatory effects of microfine MBBT in the respiratory tract, caution is warranted 2 
against the use of the material in applications that could lead to exposure of the 3 
consumer’s lungs by inhalation. This Opinion therefore does not apply to such 4 
applications that might lead to exposure of the consumer’s lungs to MBBT nanoparticles 5 
by inhalation. 6 
It should also be noted that this Opinion is based on the currently available scientific 7 
evidence, which shows an overall very low dermal absorption of MBBT in nano- or larger 8 
particle forms. If any new evidence emerges in the future to show that the nano-form of 9 
MBBT used in cosmetic products can penetrate skin (healthy, compromised, sunburnt or 10 
damaged skin) in any significant amounts to reach viable cells, the SCCS may consider 11 
revising this assessment.  12 
The in vitro genotoxicity assessment of MBBT was negative in two different test systems. 13 
These tests were appropriately applied and demonstrate that there was no evidence for 14 
chromosomal damage or mutagenicity when mammalian cells were exposed to both non-15 
micronised and nano-forms of MBBT. Although these test data are accepted by the SCCS, 16 
no experimental data on uptake/internalisation of the particle by cells has been provided.  17 
In addition, the SCCS has the following concerns: 18 
- In the study in rats, clinical effects (pain and vocalisation) after dermal application were 19 
noted at concentrations of 20% (500mg a.i. /kg bw/d and higher). In the carcinogenicity 20 
study, scabs were seen at a dose level of 100 mg a.i./kg/bw/day and higher. It is 21 
worthwhile to monitor possible irritation effects via the cosmetovigilance programs.  22 
- Given the physicochemical properties (high lipophilicity) of the substance, potential 23 
bioaccumulation in selected tissues is of concern, especially over long-term use.  24 
This opinion does not address the effects of MBBT on the environment. 25 
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• MBBT (nano) at a concentration up to 10% does not pose a risk in humans after 
application on healthy, intact skin 
 
• SCCS has concerns on possible irritation effects and potential bioaccumulation in 
selected tissues is of concern 
  
• This opinion does not address the effects of MBBT (nano) on the environment. 
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